Immunsuppression und Infektionsprophylaxe nach Lungentransplantation

C. Neurohr; J. Behr

doi:10.1055/s-0030-1255762

Pneumologie, Inhaltsverzeichnis

Pneumologie 2011; 65(2): 94-102
DOI: 10.1055/s-0030-1255762

Serie: Lungentransplantation

Immunsuppression und Infektionsprophylaxe nach Lungentransplantation

Immunosuppression and Infection Prophylaxis after Lung TransplantationC. Neurohr¹ , J. Behr¹

¹Schwerpunkt Pneumologie (Leiter Prof. Dr. J. Behr), Medizinische Klinik und Poliklinik I – Campus Großhadern (Direktor Prof. Dr. G. Steinbeck), Klinikum der Universität München

Abstract

Zusammenfassung

Die Lungentransplantation (LTX) ist ein etabliertes Therapieverfahren für Lungenerkrankungen im Endstadium. Hauptursachen für die unbefriedigenden Langzeitüberlebensraten sind Infektionen und das Bronchiolitis-obliterans-Syndrom (BOS). Für beide Komplikationen spielt eine optimale immunsuppressive Strategie eine entscheidende Rolle. Über 60 % der Organempfänger erhalten eine Induktionstherapie, ohne dass bisher ein signifikanter Vorteil bezüglich Langzeitüberleben in kontrollierten Studien demonstriert wurde. Die große Mehrheit der Patienten wird lebenslang mit einer dreifach immunsuppressiven Erhaltungstherapie, bestehend aus einem Calcineurin-Inhibitor, einem Zellzyklus-Inhibitor und einem oralen Kortikosteroid, behandelt. Eine eindeutige Überlegenheit in Bezug auf Langzeitüberleben konnte bisher jedoch für keine der spezifischen Immunsuppressiva-Kombination gezeigt werden. Ob die neueren Proliferations-Signal-Inhibitoren Sirolimus und Everolimus signifikante Vorteile bieten, ist noch nicht abschließend zu beurteilen. Zur Therapie des BOS werden eine Umstellung der Erhaltungstherapie, eine erneute Induktionstherapie, inhalatives Cyclosporin A sowie u. a. Azithromyzin, extrakorporale Photopherese und Lymphsystembestrahlung angewendet. Die Infektionsprophylaxe nach LTX spielt eine entscheidende Rolle bei der Vermeidung von akuten Komplikationen und auch in der Verhinderung des BOS. Insbesondere zur Prophylaxe einer Pneumocystis- und Cytomegalievirus-Erkrankung stehen effektive medikamentöse Optionen zur Verfügung. Darüber hinaus wurde auch die Kolonisierung mit Pseudomonas aeruginosa und Aspergillus-Spezies als Risikofaktor für BOS erkannt. Entsprechende prophylaktische bzw. prä-emptive Therapieansätze finden daher in unterschiedlichem Ausmaß in den meisten Transplantationszentren Anwendung.

Abstract

Lung transplantation (LTX) is an established therapeutic option for end-stage lung diseases. The main reasons for limited long-term survival rates are infections and bronchiolitis obliterans syndrome (BOS). An optimal immunosuppressive regimen is of critical importance for the prevention of both complications. Induction therapy is used in approximately 60 % of recipients. However, there are no controlled trials demonstrating a significant long-term survival benefit. The vast majority of patients receive a triple maintenance immunosuppressive therapy consisting of a calcineurin-inhibitor, a cell cycle inhibitor and corticosteroids. So far, no specific immunosuppressive drug combination has proven superiority regarding long-term survival rates. The potential benefits of the proliferation signal inhibitors sirolimus and everolimus remain to be elucidated. Therapeutic options for BOS encompass a switch in maintenance therapy, renewed induction therapy, aerolised cyclosporine, azithromycine, extracorporeal photopheresis and total lymphoid irradiation. Infection prophylaxis after LTX plays a pivotal role to guard against acute complications and for the prevention of BOS. In particular, prophylaxis for pneumocystis and cytomegalovirus disease is very effective. Moreover, colonisation with Pseudomonas aeruginosa and Aspergillus spp. was identified as risk factor for BOS. Consequently, in most transplant centres prophylactic and pre-emptive therapeutic approaches are applied in varying degrees.

Volltext

Referenzen

Literatur

1 Christie J D, Edwards L B, Aurora P et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report-2009. J Heart Lung Transplant. 2009; 28 1031-1049
2 Palmer S M, Miralles A P, Lawrence C M et al. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest. 1999; 116 127-133
3 Wiebe K, Harringer W, Wahlers T et al. ATG induction therapy and the incidence of bronchiolitis obliterans after lung transplantation: does it make a difference?. Transplant Proc. 1998; 30 1517-1518
4 Wain J C, Wright C D, Ryan D P. Induction immunosuppression for lung transplantation with OKT3. Ann Thorac Surg. 1999; 67 187-193
5 Brock M V, Borja M C, Ferber L et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant. 2001; 20 1282-1290
6 Abramowicz D, Schandene L, Goldman M et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation. 1989; 47 606-608
7 Ding I B, Baumgartner R A, Schwaiblmair M, Behr J. Administration of anti-interleukin-2Ralpha monoclonal antibody in bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2003; 75 1767-1769
8 Burton C M, Andersen C B, Jensen A S et al. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab. J Heart Lung Transplant. 2006; 25 638-647
9 Garrity Jr. E R, Villanueva J, Bhorade S M et al. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation. 2001; 71 773-777
10 McCurry K R, Iacono A, Zeevi A et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg. 2005; 130 528-537
11 van Loenhout K C, Groves S C, Galazka M et al. Early outcomes using alemtuzumab induction in lung transplantation. Interact Cardiovasc Thorac Surg. 2010; 10 190-194 [Epub 2009 Nov 25]
12 Hoffmeyer F, Hoeper M M, Spiekerkotter E et al. Azathioprine withdrawal in stable lung and heart/lung recipients receiving cyclosporine-based immunosuppression. Transplantation. 2000; 70 522-525
13 Korom S, Boehler A, Weder W. Immunosuppressive therapy in lung transplantation: state of the art. Eur J Cardiothorac Surg. 2009; 35 1045-1055 [Epub 2009 Apr 5]
14 Borel J F, Feurer C, Gubler H U, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976; 6 468-475
15 Levy G, Thervet E, Lake J, Uchida K. Consensus on Neoral C(2): Expert Review in Transplantation (CONCERT) Group. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation. 2002; 73 (9 Suppl) 12-18
16 Nemati E, Einollahi B, Taheri S et al. Cyclosporine trough (c0) and 2-hour postdose (c2) levels: which one is a predictor of graft loss?. Transplant Proc. 2007; 39 1223-1224
17 Glanville A R, Morton J M, Aboyoun C L et al. Cyclosporine C2 monitoring improves renal dysfunction after lung transplantation. J Heart Lung Transplant. 2004; 23 1170-1174
18 Glanville A R, Aboyoun C L, Morton J M et al. Cyclosporine C2 target levels and acute cellular rejection after lung transplantation. J Heart Lung Transplant. 2006; 25 928-934
19 Taylor J L, Palmer S M. Critical care perspective on immunotherapy in lung transplantation. J Intensive Care Med. 2006; 21 327-344
20 Ragette R, Kamler M, Weinreich G et al. Tacrolimus pharmacokinetics in lung transplantation: new strategies for monitoring. J Heart Lung Transplant. 2005; 24 1315-1319
21 Knoop C, Thiry P, Saint-Marcoux F et al. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. Am J Transplant. 2005; 5 1477-1482
22 Reichenspurner H. Overview of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant. 2005; 24 119-130
23 Keenan R J, Konishi H, Kawai A et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg. 1995; 60 580-584
24 Treede H, Klepetko W, Reichenspurner H. et al.; Munich and Vienna Lung Transplant Group . Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant. 2001; 20 511-517
25 Zuckermann A, Reichenspurner H, Birsan T et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. J Thorac Cardiovasc Surg. 2003; 125 891-900
26 Reichenspurner H, Glanville A, Christina A. et al. and European and Australian Investigators in Lung Transplantation . Complete 3 Year Analysis of a Prospective Randomized International Multi-Center Investigator Driven Study Comparing Tacrolimus and Cyclosporin A, Both in Combination with MMF and Steroids after Lung Transplantation in 249 Patients. J Heart Lung Transplant. 2008; 27 S205-S206
27 Hachem R R, Yusen R D, Chakinala M M et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant. 2007; 26 1012-1018
28 Starnes V A. Heart-lung transplantation: an overview. Cardiol Clin. 1990; 8 159-168
29 Azzola A, Havryk A, Chhajed P et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation. 2004; 77 275-280
30 Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 1998; 66 507-515
31 Mathew T H. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 1998; 65 1450-1454
32 Palmer S M, Baz M A, Sanders L et al. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation. 2001; 71 1772-1776
33 McNeil K, Glanville A R, Wahlers T et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation. 2006; 81 998-1003
34 Wali R K, Mohanlal V, Ramos E et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant. 2007; 7 1572-1583
35 Fairbanks K D, Eustace J A, Fine D et al. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl. 2003; 9 1079-1085
36 Snell G I, Levvey B J, Chin W et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant. 2002; 21 540-546
37 Groetzner J, Wittwer T, Kaczmarek I et al. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation. 2006; 81 355-360
38 Venuta F, De Giacomo T, Rendina E A et al. Recovery of chronic renal impairment with sirolimus after lung transplantation. Ann Thorac Surg. 2004; 78 1940-1943
39 Snell G I, Levvey B J, Chin W et al. Rescue therapy: a role for sirolimus in lung and heart transplant recipients. Transplant Proc. 2001; 33 1084-1085
40 Ussetti P, Laporta R, de Pablo A et al. Rapamycin in lung transplantation: preliminary results. Transplant Proc. 2003; 35 1974-1977
41 King-Biggs M B, Dunitz J M, Park S J et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation. 2003; 75 1437-1443
42 Groetzner J, Kur F, Spelsberg F. et al.; Munich Lung Transplant Group . Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant. 2004; 23 632-638
43 Chhajed P N, Dickenmann M, Bubendorf L et al. Patterns of pulmonary complications associated with sirolimus. Respiration. 2006; 73 367-374
44 Bhorade S M, Ahya V, Kotloff R et al. Long Term Follow-Up in the AIRSAC Trial, a Multicenter Randomized Clinical Trial in Lung Transplant Recipients. J Heart and Lung Transplant. 2009; 28 S119-S120
45 Neumayer H H. Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments. Transplantation. 2005; 79 S72-S75
46 Snell G I, Valentine V G, Vitulo P. et al.; RAD B159 Study Group . Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant. 2006; 6 169-177
47 Strueber M, Stefan F, Simon A R et al. Everolimus Versus Mycophenolatemofetil in De Novo Immunosuppression after Lung Transplantation – Interims Analysis of a Prospective, Randomized, Clinical Trial. J Heart and Lung Transplant. 2008; 27 205
48 Gullestad L, Iversen M, Mortensen S A et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation. 2010; 89 864-872
49 Otton J, Hayward C S, Keogh A M et al. Everolimus-associated pneumonitis in 3 heart transplant recipients. J Heart Lung Transplant. 2009; 28 104-106 [Epub 2008 Dec 12]
50 Pratap B, Abraham G, Srinivas C N, Bhaskar S. Post-renal transplant hemolytic uremic syndrome following combination therapy with tacrolimus and everolimus. Saudi J Kidney Dis Transpl. 2007; 18 609-612
51 Morton J M, Williamson S, Kear L M et al. Therapeutic drug monitoring of prednisolone after lung transplantation. J Heart Lung Transplant. 2006; 25 557-563
52 Borro J M, Solé A, De la Torre M et al. Steroid withdrawal in lung transplant recipients. Transplant Proc. 2005; 37 3991-3993
53 Shitrit D, Bendayan D, Sulkes J et al. Successful steroid withdrawal in lung transplant recipients: result of a pilot study. Respir Med. 2005; 99 596-601
54 Keogh A M, Arnold R H, Macdonald P S et al. A randomized trial of tacrolimus (FK506) versus total lymphoid irradiation for the control of repetitive rejection after cardiac transplantation. J Heart Lung Transplant. 2001; 20 1331-1334
55 Diamond D A, Michalski J M, Lynch J P, Trulock E P. Efficacy of total lymphoid irradiation for chronic allograft rejection following bilateral lung transplantation. Int J Radiat Oncol Biol Phys. 1998; 41 795-800
56 Fisher A J, Rutherford R M, Bozzino J et al. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant. 2005; 5 537-543
57 Verleden G M, Lievens Y, Dupont L J et al. Efficacy of total lymphoid irradiation in azithromycin nonresponsive chronic allograft rejection after lung transplantation. Transplant Proc. 2009; 41 1816-1820
58 Astor T L, Weill D. Extracorporeal photopheresis in lung transplantation. J Cutan Med Surg. 2003; 7 20-24
59 Morrell M R, Despotis G J, Lublin D M et al. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2010; 29 424-431 [Epub 2009 Oct 22]
60 Benden C, Speich R, Hofbauer G F et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation. 2008; 86 1625-1627
61 Williams T J, Verleden G M. Azithromycin: a plea for multicenter randomized studies in lung transplantation. Am J Respir Crit Care Med. 2005; 172 657-659
62 Verleden G M, Dupont L J. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2004; 77 1465-1467
63 Vanaudenaerde B M, Meyts I, Vos R et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J. 2008; 32 832-843
64 Gottlieb J, Szangolies J, Koehnlein T et al. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2008; 85 36-41
65 Vos R, Vanaudenaerdea B M, Schoonisa A et al. Azithromycin for Bronchiolitis Obliterans Syndrome after Lung Transplantation. J Heart and Lung Transplant. 2010; 29 S94
66 Iacono A T, Corcoran T E, Griffith B P et al. Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans. Eur Respir J. 2004; 23 384-390
67 Iacono A T, Johnson B A, Grgurich W F et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006; 354 141-150
68 Ide N, Nagayasu T, Matsumoto K et al. Efficacy and safety of inhaled tacrolimus in rat lung transplantation. J Thorac Cardiovasc Surg. 2007; 133 548-553
69 Behr J, Zimmermann G, Baumgartner R. et al.; Munich Lung Transplant Group . Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. J Aerosol Med Pulm Drug Deliv. 2009; 22 121-130
70 Sarahrudi K, Estenne M, Corris P et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg. 2004; 127 1126-1132
71 Jordan S C, Quartel A W, Czer L S et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation. 1998; 66 800-805
72 Bhorade S M, Stern E. Immunosuppression for lung transplantation. Proc Am Thorac Soc. 2009; 6 47-53
73 Fishman J A. Infection in solid-organ transplant recipients. N Engl J Med. 2007; 357 2601-2614
74 Remund K F, Best M, Egan J J. Infections relevant to lung transplantation. Proc Am Thorac Soc. 2009; 6 94-100
75 Avery R K, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant. 2008; 8 9-14 [Epub 2007 Dec 18]
76 Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007; 82 1052-1059
77 Hodson E M, Craig J C, Strippoli G F, Webster A C. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2008; 16 CD003774
78 Fishman J A, Emery V, Freeman R et al. Cytomegalovirus in transplantation – challenging the status quo. Clin Transplant. 2007; 21 149-158
79 Weigt S S, Elashoff R M, Huang C et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant. 2009; 9 1903-1911 [Epub 2009 May 13]
80 Solé A, Salavert M. Fungal infections after lung transplantation. Curr Opin Pulm Med. 2009; 15 243-253
81 Campos S, Caramori M, Teixeira R et al. Bacterial and fungal pneumonias after lung transplantation. Transplant Proc. 2008; 40 822-824
82 Hafkin J, Blumberg E. Infections in lung transplantation: new insights. Curr Opin Organ Transplant. 2009; 14 483-487

Dr. med. Claus Neurohr

Medizinische Klinik und Poliklinik I
Klinikum der Universität München – Großhadern

Marchioninistr. 15
81377 München

eMail: claus.neurohr@med.uni-muenchen.de